← Back to Search

Radiation Therapy

Degarelix for Prostate Cancer

Phase 3
Waitlist Available
Led By Michael Zelefsky, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial will compare the two different treatments to see which one is more effective in treating your prostate cancer.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Biopsy

Trial Design

2Treatment groups
Experimental Treatment
Group I: stereotactic body radiosurgery (SBRT)Experimental Treatment1 Intervention
SBRT 8 Gy x 5
Group II: Degarelix in conjunction with stereotactic body radiosurgeryExperimental Treatment2 Interventions
Degarelix monthly for 6 months SBRT 8 Gy x 5
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Degarelix
2002
Completed Phase 3
~3600
stereotactic body radiosurgery (SBRT)
2017
Completed Phase 3
~60

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,936 Previous Clinical Trials
588,842 Total Patients Enrolled
132 Trials studying Prostate Cancer
52,026 Patients Enrolled for Prostate Cancer
Ferring PharmaceuticalsIndustry Sponsor
314 Previous Clinical Trials
440,827 Total Patients Enrolled
51 Trials studying Prostate Cancer
17,811 Patients Enrolled for Prostate Cancer
University of Texas Southwestern Medical CenterOTHER
1,048 Previous Clinical Trials
1,054,229 Total Patients Enrolled
16 Trials studying Prostate Cancer
2,104 Patients Enrolled for Prostate Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this study taking place across the country?

"There are 10 sites enrolling patients in this trial, including Memorial Sloan Kettering Commack in Commack, New york, Baptist Alliance MCI in Miami, and other locations."

Answered by AI

Are there any dangers associated with SBRT that patients should know about?

"There is some evidence suggesting stereotactic body radiosurgery (SBRT) is effective, as this treatment is currently in Phase 3 clinical trials. Furthermore, data collected thus far supports that SBRT is a safe medical intervention."

Answered by AI

What is the scientific community's stance on SBRT after other research teams have looked into it?

"Currently, there are 32 clinical trials underway studying stereotactic body radiosurgery (SBRT). Of those live trials, 8 are in Phase 3. The majority of trials for stereotactic body radiosurgery (SBRT) are based in Los Angeles, California; however, there are 1,398 locations running studies for this treatment across the globe."

Answered by AI

Does this research build on any previous findings?

"At this moment in time, there are 32 ongoing clinical trials for stereotactic body radiosurgery (SBRT) being conducted in 545 cities and 14 countries. The first-ever study of its kind was held 8 years ago in 2012. This initial trial, which was sponsored by Ferring Pharmaceuticals, had a sample size of 41 patients and completed N/A stage of drug approval process. In the intervening years since 2012, a total of 61 studies have been wrapped up."

Answered by AI

Are there any places left for people in this clinical trial?

"This study is not currently looking for participants, according to the information on clinicaltrials.gov. This page was created on March 28th, 2017 and last updated on March 1st, 2022. Although this particular trial isn't running at the moment, there are 1391 other trials that are seeking candidates right now."

Answered by AI
~7 spots leftby May 2025